Representative supporting data and codes for the data structure in the Gioia method
| Second-order themes | Representative first-order data | Representative codes | Corpus references |
|---|---|---|---|
| Traceability | The ability to better trace the medical products using blockchain and IoMT | Traceability; collaboration; governance of traceability efforts; traceability in drug supply chains; implementing traceability; improving traceability | 9, 34, 46, 48, 54, 57, 66, 74, 86, 93 |
| Visibility | The ability to handle uncertainty by improving visibility in cold supply chains | Visibility; supply chain visibility; coordination | 3, 4, 99, 107, 109, 112 |
| Transparency | The ability to offer transparent data integration and analysis | Transparency; data transparency; improving transparency | 1, 5, 6, 7, 55, 56, 59, 60, 81, 92, 104, 105, 106, 107, 109, 112 |
| Accessibility | The ability to get better access to vaccines and medicines supply using IoT | Vaccine offering | 3, 4, 16, 24, 46, 48, 67, 68, 89, 97, 104, 112, 114 |
| Supply base optimisation | The ability to improve procurement processes by accessing suppliers via their supply chains using blockchain | Procurement; Innovative procurement; Procurement 4.0 | 57, 73, 74, 90, 92 |
| Diagnosis | The ability to offer faster diagnosis using IoMT | Early diagnosis | 7, 73 |
| Personalisation | The ability to offer personalised treatment to patients | Personalised treatment | 11, 20, 41, 56, 99, 107 |
| Sustainability | The ability to recycle and produce green products and to minimise waste using big data analytics | Sustainability; green manufacturing; improved sustainability | 4, 17, 21, 23, 39, 41, 63, 68, 81, 85, 95, 97, 98, 99, 100, 107 |
| Forecasting | The ability to improve operational performance by faster and efficient responses to drug shortages | Demand forecasting | 4, 29, 35, 50, 77, 83 |
| Privacy and security | The vulnerability to data breach and privacy issue for both patients’ data and new drug development | Privacy; privacy-preserving issue; protecting privacy | 9, 12, 29, 33, 40, 49, 51, 54, 56, 57, 58, 61, 62, 67, 68, 69, 71, 73, 74, 75, 76, 79, 81, 85, 89, 91, 93, 94, 96, 99, 101, 107, 109, 112, 114 |
| Complexity | The complexity of dealing with traceability in drug supply chains | Complexity; handling complexity | 1, 5, 6, 7, 8, 9, 15, 33, 37, 40, 43, 46, 48, 55, 56, 57, 59, 60, 62, 66, 68, 73, 74, 81, 84, 85, 86, 90, 92, 94, 95, 96, 97, 99, 100, 104, 105, 106, 107, 109, 112 |
| Regulations | The legislation creates a burden for I4.0 implementation | Legislation issues | 81, 92, 99, 107, 109 |
| Financial issues | The uncertain development cost challenge and imposed financial burden | Financial issues; development cost; financial cost | 62, 85, 86, 95 |
| Managerial support | The lack of support from top management to implement I4.0 technologies in the supply chain | Top management support; collaboration; management support | 32, 57, 61 |
| Data scarcity | The lack of suitable data for machine learning algorithms predictions | Limited data access | 18, 29, 32, 49, 50, 58 |
| Second-order themes | Representative first-order data | Representative codes | Corpus references |
|---|---|---|---|
| Traceability | The ability to better trace the medical products using blockchain and IoMT | Traceability; collaboration; governance of traceability efforts; traceability in drug supply chains; implementing traceability; improving traceability | 9, 34, 46, 48, 54, 57, 66, 74, 86, 93 |
| Visibility | The ability to handle uncertainty by improving visibility in cold supply chains | Visibility; supply chain visibility; coordination | 3, 4, 99, 107, 109, 112 |
| Transparency | The ability to offer transparent data integration and analysis | Transparency; data transparency; improving transparency | 1, 5, 6, 7, 55, 56, 59, 60, 81, 92, 104, 105, 106, 107, 109, 112 |
| Accessibility | The ability to get better access to vaccines and medicines supply using IoT | Vaccine offering | 3, 4, 16, 24, 46, 48, 67, 68, 89, 97, 104, 112, 114 |
| Supply base optimisation | The ability to improve procurement processes by accessing suppliers via their supply chains using blockchain | Procurement; Innovative procurement; Procurement 4.0 | 57, 73, 74, 90, 92 |
| Diagnosis | The ability to offer faster diagnosis using IoMT | Early diagnosis | 7, 73 |
| Personalisation | The ability to offer personalised treatment to patients | Personalised treatment | 11, 20, 41, 56, 99, 107 |
| Sustainability | The ability to recycle and produce green products and to minimise waste using big data analytics | Sustainability; green manufacturing; improved sustainability | 4, 17, 21, 23, 39, 41, 63, 68, 81, 85, 95, 97, 98, 99, 100, 107 |
| Forecasting | The ability to improve operational performance by faster and efficient responses to drug shortages | Demand forecasting | 4, 29, 35, 50, 77, 83 |
| Privacy and security | The vulnerability to data breach and privacy issue for both patients’ data and new drug development | Privacy; privacy-preserving issue; protecting privacy | 9, 12, 29, 33, 40, 49, 51, 54, 56, 57, 58, 61, 62, 67, 68, 69, 71, 73, 74, 75, 76, 79, 81, 85, 89, 91, 93, 94, 96, 99, 101, 107, 109, 112, 114 |
| Complexity | The complexity of dealing with traceability in drug supply chains | Complexity; handling complexity | 1, 5, 6, 7, 8, 9, 15, 33, 37, 40, 43, 46, 48, 55, 56, 57, 59, 60, 62, 66, 68, 73, 74, 81, 84, 85, 86, 90, 92, 94, 95, 96, 97, 99, 100, 104, 105, 106, 107, 109, 112 |
| Regulations | The legislation creates a burden for I4.0 implementation | Legislation issues | 81, 92, 99, 107, 109 |
| Financial issues | The uncertain development cost challenge and imposed financial burden | Financial issues; development cost; financial cost | 62, 85, 86, 95 |
| Managerial support | The lack of support from top management to implement I4.0 technologies in the supply chain | Top management support; collaboration; management support | 32, 57, 61 |
| Data scarcity | The lack of suitable data for machine learning algorithms predictions | Limited data access | 18, 29, 32, 49, 50, 58 |
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.